Selexis Working with ImmuNext to Advance Potential Treatment for IBD

Selexis Working with ImmuNext to Advance Potential Treatment for IBD
Selexis and ImmuNext have recently inked a license agreement, giving ImmuNext access to research cell banks from Selexis’ SURE technology Platform. Under the terms of the agreement, ImmuNext will use Selexis cell banks to further develop its anti-CD40 ligand antibody, a potential treatment for chronic autoimmune diseases, including inflammatory bowel disease (IBD). Mammalian cell culture technology is usually used as a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *